Design, synthesis and evaluation of protease-activated anti-cancer prodrugs at University of Bradford on FindAPhD.com

Dr Rob Falconer, Prof Paul Loadman Applications accepted all year round Self-Funded PhD Students Only

Institution website

Add
to
shortlist

Remove
from
shortlist

Institution
profile

Bradford United Kingdom Biochemistry Cancer / Oncology Cell Biology / Development Immunology Pharmaceutical / Medicinal Chemistry Pharmacology / Toxicology Pharmacy / Pharmaceutics

About the Project

Matrix metalloproteinases (MMPs) are a family of endoproteases that are overexpressed in tumours and play crucial roles in many tumourigenic processes, not least tumour invasion and angiogenesis. The concept behind our technology is that the increased expression and activity of MMPs within the tumour microenvironment, relative to normal tissues, can be exploited to selectively release potent chemotherapeutics from non-toxic peptide conjugates. The result is high levels of the active agent in the tumour and negligible drug levels in ’normal’ tissues.

Conjugation of a peptide to the active drug molecule renders it inactive until such time that it is activated by MMPs in the tumour. The MMP then cleaves the peptide, resulting in release of the active drug selectively in the tumour microenvironment. The ICT has already successfully used this technology to improve the therapeutic index of a colchicine derivative (ICT2588, see Cancer Research, 2010, 70, 6902-6912), which is now licensed to University of Bradford spin-out company Incanthera Ltd (www.incanthera.com) and received global press coverage at the British Science Festival 2011 (e.g. http://www.bbc.co.uk/news/science-environment-14855666). ICT2588 is about to enter Phase I clinical trials. The group additionally has strong links with Stanford University (USA), having commercialised an MMP-activated ‘theranostic’ version of ICT2588, which simultaneously allows MRI imaging and cancer therapy (see Small, 2014, 10, 566-575, and Molecular Cancer Therapeutics, 2017, 16, 1909-1921).

The student will join a successful, motivated multidisciplinary team with expertise in medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics. The project will involve the design, synthesis and biological evaluation of the next generation of MMP-activated prodrugs, with the aim of identifying an agent to progress towards advanced preclinical testing and ultimately the clinic.

Specific aims:
(1) Synthesis of novel peptide-drug conjugates, utilizing modern automated solid-phase peptide technology and/or
(2) Study of the metabolism of synthesized conjugates in tumour and normal tissues in vitro, using LC-MS;
(3) In vivo assessment of the most promising compound – pharmacokinetics and efficacy in a mouse model.

Funding Notes

This is a self-funded project; applicants will be expected to pay their own fees or have access to suitable third-party funding. In addition to the university's standard tuition fees, bench fees of £10,000 per year also apply to this project.

References

Entry requirements

At least 2:1 honours degree in Chemistry, Medicinal Chemistry, Pharmacy or related subjects. An MSc in any of these areas is an advantage.
For full details of our entry requirements, please visit our website.

Email Now

Recipient *

Your first name *

Your last name *

Your telephone number

Your e-mail address *

Your CV (2MB limit)

Where are you currently living? *

Your nationality *

Insert previous message

Your message * (please edit as appropriate)

You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here

* required field

Send a copy to me for my own records

The information you submit to University of Bradford will only be used by them or their data partners to deal with your enquiry, according to their privacy notice. For more information on how we use and store your data, please read our privacy statement.